Articles by Jiaxin (Jason) Niu, MD

Jiaxin (Jason) Niu, MD, and Amanda Edmond, PA-C, walk through an 8-week treatment update for a patient on subcutaneous amivantamab plus lazertinib: grade 2 acneiform rash and paronychia by week 3; bilateral lower-extremity edema with low albumin by week 6; and partial response on restaging at week 8.

Amanda Edmond, PA-C, explains that lower-extremity edema from amivantamab, due to its MET-targeting mechanism, does not respond well to diuretics and is primarily managed with dose pausing or dose reduction rather than with medication.

Jiaxin (Jason) Niu, MD, explains which patients with EGFR-mutated non-small cell lung cancer (NSCLC) benefit most from combination therapy over osimertinib monotherapy, citing brain metastases, liver metastases, elevated baseline ctDNA, and TP53 co-mutation as high-risk features present in up to 80% to 90% of patients.

Jiaxin (Jason) Niu, MD, and Amanda Edmond, PA-C, discuss how patient goals shape the choice between osimertinib monotherapy and combination therapy in EGFR-mutated non-small cell lung cancer (NSCLC).

Jiaxin (Jason) Niu, MD, reviews first-line treatment options for EGFR-mutant metastatic non–small cell lung cancer (NSCLC), noting that osimertinib monotherapy was the preferred first-line therapy based on the FLAURA trial, which began in 2018.

Jiaxin (Jason) Niu, MD, and Amanda Edmond, PA-C, open a virtual tumor board on first-line treatment for EGFR-mutated metastatic non–small cell lung cancer (NSCLC).